Local treatment for the prognosis of hormone-sensitive metastatic prostate cancer: a Meta-analysis
10.3760/cma.j.issn.1000-6702.2017.10.017
- VernacularTitle:局部治疗对激素敏感性转移性前列腺癌预后影响的Meta分析
- Author:
Qiang ZHAO
1
;
Yong YANG
;
Li LI
;
Peng DU
;
Shuo WANG
;
Xingxing TANG
;
Chao AN
;
Yongpeng JI
;
Ning ZHANG
Author Information
1. 恶性肿瘤发病机制及转化研究教育部重点实验室北京大学肿瘤医院暨北京市肿瘤防治研究所泌尿外科
- Keywords:
Prostatic neoplasms,metastatic;
Local treatment;
Radical prostatectomy;
Radiotherapy;
Meta-analysis
- From:
Chinese Journal of Urology
2017;38(10):791-796
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of local treatment for the prognosis of hormonesensitive metastatic prostate cancer.Methods A systematic review of the literature about local treatment for the prognosis of hormone-sensitive metastatic prostate cancer was performed,searching Medline,Embase,Cochrane Library,CBM,CNKI,VIP and Wan Fang database from January 2001 to October 2016.Two authors reviewed the records to identify comparative studies.A meta-analysis was conducted using Review Manager 5.0.Results Five studies were enrolled,including 29 354 patients.Meta-analysis showed that,compared with no local treatment,local treatment had a significant beneficial effect in 5-year overall survival rate (OR =0.18,95 ％ CI 0.15-0.22,P ＜ 0.01),5-year disease specific survival rate (OR =0.39,95 ％ CI 0.31-0.49,P＜0.01) as well as 3-year overall survival rate (OR =0.47,95％ CI 0.35-0.62,P＜0.01).Sub-group analysis showed that,compared with no local treatment,prostatectomy had a significant beneficial effect in 5-year overall survival rate (OR =0.17,95 ％ CI 0.12-0.25,P ＜ 0.01),5-year disease specific survival rate (OR =0.30,95％ CI 0.22-0.40,P ＜0.01) as well as 3-year overall survival rate (OR=0.25,95％CI 0.19-0.32,P ＜0.01),and external beam radiation therapy only had a significant beneficial effect in 3-year overall survival rate (OR =0.54,95％ CI 0.42-0.69,P ＜ 0.01).Conclusions Prostatectomy and external beam radiation therapy may have a survival benefit for hormone-sensitive metastatic prostate cancer.Prospective randomized controlled studies are necessary because of the limits of current studies.
